Edgar Filing: ADVENTRX PHARMACEUTICALS INC - Form 3

ADVENTRX PHARMACEUTICALS INC

Form 3

March 09, 2006

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

Number:

3235-0104

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Expires:

January 31, 2005

0.5

Estimated average burden hours per response...

OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement ADVENTRX PHARMACEUTICALS INC [ANX] A Cantwell Mark Joseph (Month/Day/Year) 02/28/2006 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 6725 MESA RIDGE (Check all applicable) RD., Â SUITE 100 (Street) 6. Individual or Joint/Group 10% Owner Director _X__ Officer Other Filing(Check Applicable Line) (give title below) (specify below) _X_ Form filed by One Reporting VP, Research & Development Person SAN DIEGO, CAÂ 92121 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities

Beneficially Owned (Instr. 4) (Instr. 4)

Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	
		(Instr. 4)	Price of	Derivative	(Instr. 5)
	Date Exercisable Expiration Date	Title Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect	

Edgar Filing: ADVENTRX PHARMACEUTICALS INC - Form 3

						(Instr. 5)	
Option to Purchase Common Stock	11/03/2004(1)	12/30/2008	Common Stock	50,000	\$ 1.4	D	Â
Option to Purchase Common Stock	01/01/2006(2)	07/13/2015	Common Stock	50,000	\$ 2.3	D	Â
Option to Purchase Common Stock	01/01/2007(3)	01/01/2016	Common Stock	50,000	\$ 4.75	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
reporting of hor runner runners	Director	10% Owner	Officer	Other	
Cantwell Mark Joseph 6725 MESA RIDGE RD. SUITE 100 SAN DIEGO Â CA Â 92121	Â	Â	VP, Research & Development	Â	

Signatures

/s/ Mark J. Cantwell	03/09/2006		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option is fully vested as the date of this report.
- (2) This option vested and became exercisable with respect to one-fourth of the shares on January 1, 2006, and will vest and become exercisable with respect to one-forty eight of the shares at the end of each successive month after January 1, 2006.
- (3) This option will vest and become exercisable with respect to one-fourth of the shares on January 1, 2007 and as to one-forty-eighth of the shares at the end of each successive month after January 1, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2